MRIGlobal CIO Named One of The Top 25 Women Chief Innovation Officers of 2024
This story was originally posted at TheWomenWeAdmire.com
Women We Admire is pleased to announce The Top 25 Women Chief Innovation Officers of 2024. As strategic risk-takers, Chief Innovation Officers (CINOs) embrace change and challenge the status quo to propel their companies forward. Renowned for their collaborative approach, CINOs harness the power of diverse perspectives within their teams, fostering an environment where new ideas can flourish. Their innovative strategies not only drive growth but also inspire a culture of creativity and resilience across their organizations.
Please join us in celebrating Amy Manning-Bog as one of The Top 25 Women Chief Innovation Officers of 2024.
Amy Manning-Bog¸ Chief Innovation Officer, MRIGlobal
Amy Manning-Bog is the Chief Innovation Officer of MRIGlobal, a world leader in applied science and technology research. Manning-Bog is responsible for leading the identification and translation of MRIGlobal proprietary intellectual property into commercialization opportunities through licensing, royalties, and new business venture start-ups. She also leads MRIGlobal’s translational development team.
Manning-Bog has built her career on being a scientific leader and executive in discovery research and translation with a history of achievement in strategic planning, operations, and financial goals in small and mid-sized companies. She has led from concept to development of many innovative, novel therapeutics, including biologics, small molecules, and gene-modifying agents across multiple domains, including neuroscience, oncology, and metabolic diseases. She has a strong track record of leading and contributing effectively in multidisciplinary and team-based environments that are fast-paced, collaborative, and scientifically rigorous.
Manning-Bog is an advocate for protecting voting rights and has served as a mentor for young women in the Cristo Rey Academy program in the San Francisco Bay Area. She joined MRIGlobal in 2022, following seven years with Atreca, Inc. While there, she served in various roles, contributing to key decisions regarding platform strategy, pipeline development, and program advancement for internal studies and external-facing collaborations with large pharmaceutical companies. Manning-Bog¸ graduated from the University of Missouri-Kansas City with an interdisciplinary Ph.D. in Biochemistry and Molecular Biology and from Missouri State University with an undergraduate degree in biology.